- •Low positive hormone receptor breast cancer responses to neoadjuvant chemotherapy were analysed.
- •Low positive hormone receptor breast cancer has worse survival than strong positive.
- •Low positive hormone receptor breast cancer mostly expresses basal-like features.
To evaluate HER2-negative breast cancer (BC) with a low hormone receptor (HR) expression, with regard to pathological complete response (pCR) and survival, in comparison to triple-negative BC (TNBC) and strong HR-positive BC.
We compared negative [oestrogen (ER) and progesterone receptor (PR) <1%], low-positive (ER and/or PR 1–9%) and strong-positive (ER or PR 10–100%) HR-expression in neoadjuvant clinical trial cohorts (n = 2765) of BC patients. End-points were disease-free survival (DFS), distant-disease free survival (DDFS) and overall survival (OS). We performed RNA sequencing on available tumour tissue samples from patients with low-HR expression (n = 38).
Ninety-four (3.4%) patients had low HR-positive tumours, 1769 (64.0%) had strong HR-positive tumours, and 902 (32.6%) had TNBC. There were no significant differences in pCR rates between women with low HR-positive tumours (27.7%) and women with TNBC (35.5%). DFS and DDFS were also not different [for DFS, hazard ratio 1.26, 95%-CI (confidence interval) : 0.87–1.83, log-rank test p = 0.951; for DDFS, hazard ratio 1.17, 95%-CI: 0.78–1.76, log-rank test p = 0.774]. Patients with strong HR-positive tumours had a significantly lower pCR rate (pCR 9.4%; odds ratio 0.38, 95%-CI: 0.23–0.63), but better DFS (hazard ratio 0.48, 95%-CI: 0.33–0.70) and DDFS (hazard ratio 0.49, 95%-CI: 0.33–0.74) than patients with low HR-positive tumours. Molecular subtyping (RNA sequencing) of low HR-positive tumours classified these predominantly into a basal subtype (86.8%).
Low HR-positive, HER2-negative tumours have a similar clinical behaviour to TNBC showing high pCR rates and poor survival and also a basal-like gene expression signature. Patients with low HR-positive tumours should be regarded as candidates for therapy strategies targeting TNBC.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to European Journal of Cancer
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16.J Clin Oncol. 1990; 8: 1005-1018
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.Lancet. 2005; 365: 1687-1717
- Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.Ann Oncol. 2015; 26: v8-v30
- American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.Arch Pathol Lab Med. 2010; 134: 907-922
- Current status of estrogen receptors in human breast cancer.Cancer. 1975; 36: 638-644
- The immunohistochemical determination of estrogen and progesterone receptor status in breast cancer.Am J Clin Pathol. 1993; 99: 8-12
- Should immunohistochemical examination replace biochemical hormone receptor assays in breast cancer?.Am J Clin Pathol. 1993; 99: 1-3
- Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.J Clin Oncol. 1999; 17: 1474-1481
- Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study.Int J Canc. 2000; 89: 111-117
- Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005.Ann Oncol. 2005; 16: 1569-1583
- Thresholds for therapies: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2009.Ann Oncol. 2009; 20: 1319-1329
- Immunohistochemical evaluation of hormone receptor status for predicting response to endocrine therapy in metastatic breast cancer.Breast Cancer. 2006; 13: 74-83
- Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry.J Clin Oncol. 2012; 30: 729-734
- A Majority of low (1-10%) ER positive breast cancers behave like hormone receptor negative tumors.J Canc. 2014; 5: 156-165
- Effect of ASCO/CAP guidelines for determining ER status on molecular subtype.Ann Surg Oncol. 2013; 20: 87-93
- Estrogen and progesterone receptor testing in breast cancer: American Society of clinical oncology/College of American pathologists guideline update.Arch Pathol Lab Med. 2020; 144: 545-563
- Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.Lancet Oncol. 2012; 13: 135-144
- Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.N Engl J Med. 2012; 366: 299-309
- Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial.Lancet Oncol. 2016; 17: 345-356
- A Proposal for the standardization of the Immunoreactive Score (IRS) for the immunohistochemical demonstration of Estrogen-Receptors (ER-ICA) in breast cancer.Pathologe. 1987; 8: 138-140
- American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.J Clin Oncol. 2007; 25: 118-145
- Proposal for standardized definitions for efficacy endpoints in adjuvant breast cancer trials: the STEEP system.J Clin Oncol. 2007; 25: 2127-2132
- Sensitive and powerful single-cell RNA sequencing using mcSCRB-seq.Nat Commun. 2018; 9: 2937
- PiggyBac transposon tools for recessive screening identify B-cell lymphoma drivers in mice.Nat Commun. 2019; 10: 1415
- zUMIs - a fast and flexible pipeline to process RNA sequencing data with UMIs.GigaScience. 2018; 7
- Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2.Genome Biol. 2014; 15: 550
- The sva package for removing batch effects and other unwanted variation in high-throughput experiments.Bioinformatics. 2012; 28
- Absolute assignment of breast cancer intrinsic molecular subtype.J Natl Cancer Inst. 2014; 4: 107
- Which threshold for ER positivity? a retrospective study based on 9639 patients.Ann Oncol. 2014; 25: 1004-1011
- Low ER+ breast cancer: is this a distinct group?.Am J Clin Pathol. 2014; 141: 697-701
- Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer.Ann Oncol. 2017; 28: 2420-2428
- Low Estrogen Receptor (ER)–positive breast cancer and neoadjuvant systemic chemotherapy: is response similar to typical ER-positive or ER-negative disease?.Am J Clin Pathol. 2018; 150: 34-42
Published online: March 17, 2021
Accepted: February 13, 2021
Received in revised form: February 8, 2021
Received: December 3, 2020
© 2021 Elsevier Ltd. All rights reserved.